Recent news on Combipatch

Noven Reports First Quarter 2007 Financial Results  -  Apr 30, 2007
Teleborsa News,...the risk that Novogyne may not be able to realize the full value of the marketing rights for Noven's CombiPatch product; and risks and uncertainties

Noven Announces 2006 Financial Results  -  Mar 2, 2007
PharmaLive.com (press release),...the risk that Novogyne may not be able to realize the full value of the marketing rights for Noven's CombiPatch product; and risks and uncertainties

Noven Reports Third Quarter 2006 Financial Results  Nov 6, 2006
...to Novogyne and Novartis Pharma; the risk that Novogyne may not be able to realize the full value of the marketing rights for Noven's CombiPatch product; and ... -Business Wire (press release), MARKET INSIGHT: Noven Pharmaceuticals Poised for an Upside Move  Oct 19, 2006
CombiPatch is the first combination estrogen/progestin transdermal patch marketed under the brand name Estalis outside the United States. ... -Inside Futures, Noven Reports Second Quarter 2006 Financial Results; Quarter ...  Aug 9, 2006
...to Novogyne and Novartis Pharma; the risk thatNovogyne may not be able to realize the full value of the marketingrights for Noven's CombiPatch product; and ... -Finanzen.net



Noven Reports First Quarter 2006 Financial Results  May 1, 2006
...to Novogyne and Novartis Pharma; the risk that Novogyne may not be able to realize the full value of the marketing rights for Noven's CombiPatch product; and ... - Business Wire



Noven Provides Update on Vivelle-Dot(TM) Estrogen Patch  Jan 24, 2006
Aggregate total prescriptions for the three HT products offered by Novogyne (Vivelle-Dot(TM), original Vivelle(R) and CombiPatch(R)) increased 4% in 2005 ... - Genetic Engineering News

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional